Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.

Decock A, Ongenaert M, De Wilde B, Brichard B, Noguera R, Speleman F, Vandesompele J.

Epigenetics. 2016 Sep 6:0. [Epub ahead of print]

PMID:
27599161
2.

Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis.

Li Y, Min W, Li M, Han G, Dai D, Zhang L, Chen X, Wang X, Zhang Y, Yue Z, Liu J.

Int J Mol Med. 2016 Oct;38(4):1170-8. doi: 10.3892/ijmm.2016.2717. Epub 2016 Aug 26.

3.

Human Specific Regulation of the Telomerase Reverse Transcriptase Gene.

Zhang F, Cheng D, Wang S, Zhu J.

Genes (Basel). 2016 Jun 28;7(7). pii: E30. doi: 10.3390/genes7070030. Review.

4.

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Vera B, Martínez-Vélez N, Xipell E, Acanda de la Rocha A, Patiño-García A, Saez-Castresana J, Gonzalez-Huarriz M, Cascallo M, Alemany R, Alonso MM.

PLoS One. 2016 Jan 25;11(1):e0147211. doi: 10.1371/journal.pone.0147211. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0157619.

5.

E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma.

Chen L, Yu JH, Lu ZH, Zhang W.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):10545-54. eCollection 2015.

6.

The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients.

Samaka RM, Aiad HA, Kandil MA, Asaad NY, Holah NS.

Anal Cell Pathol (Amst). 2015;2015:919834. doi: 10.1155/2015/919834. Epub 2015 Oct 27.

7.

The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.

Liang HQ, Wang RJ, Diao CF, Li JW, Su JL, Zhang S.

Oncotarget. 2015 Oct 6;6(30):29413-27. doi: 10.18632/oncotarget.5003.

8.

DCAF4, a novel gene associated with leucocyte telomere length.

Mangino M, Christiansen L, Stone R, Hunt SC, Horvath K, Eisenberg DT, Kimura M, Petersen I, Kark JD, Herbig U, Reiner AP, Benetos A, Codd V, Nyholt DR, Sinnreich R, Christensen K, Nassar H, Hwang SJ, Levy D, Bataille V, Fitzpatrick AL, Chen W, Berenson GS, Samani NJ, Martin NG, Tishkoff S, Schork NJ, Kyvik KO, Dalgård C, Spector TD, Aviv A.

J Med Genet. 2015 Mar;52(3):157-62. doi: 10.1136/jmedgenet-2014-102681. Epub 2015 Jan 26.

9.

Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Meng P, Ghosh R.

Cell Death Dis. 2014 Aug 7;5:e1360. doi: 10.1038/cddis.2014.326. Review.

10.

E2F1 coregulates cell cycle genes and chromatin components during the transition of oligodendrocyte progenitors from proliferation to differentiation.

Magri L, Swiss VA, Jablonska B, Lei L, Pedre X, Walsh M, Zhang W, Gallo V, Canoll P, Casaccia P.

J Neurosci. 2014 Jan 22;34(4):1481-93. doi: 10.1523/JNEUROSCI.2840-13.2014.

11.

Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma.

Ma X, Gao Y, Fan Y, Ni D, Zhang Y, Chen W, Zhang P, Song E, Huang Q, Ai Q, Li H, Wang B, Zheng T, Shi T, Zhang X.

PLoS One. 2013 Sep 4;8(9):e73436. doi: 10.1371/journal.pone.0073436. eCollection 2013.

12.

MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells.

Xiao B, Tan L, He B, Liu Z, Xu R.

J Transl Med. 2013 Jul 17;11:172. doi: 10.1186/1479-5876-11-172.

13.

E2F transcription factors and digestive system malignancies: how much do we know?

Xanthoulis A, Tiniakos DG.

World J Gastroenterol. 2013 Jun 7;19(21):3189-98. doi: 10.3748/wjg.v19.i21.3189. Review.

14.

Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK.

Neuro Oncol. 2013 Jul;15(7):829-39. doi: 10.1093/neuonc/not024. Epub 2013 Mar 15.

15.

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Lötsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S.

Neuro Oncol. 2013 Apr;15(4):423-32. doi: 10.1093/neuonc/nos329. Epub 2013 Feb 7.

16.

The regulation of telomerase in oncogenesis.

Skvortzov DA, Rubzova MP, Zvereva ME, Kiselev FL, Donzova OA.

Acta Naturae. 2009 Apr;1(1):51-67.

17.

A ten-microRNA expression signature predicts survival in glioblastoma.

Srinivasan S, Patric IR, Somasundaram K.

PLoS One. 2011 Mar 31;6(3):e17438. doi: 10.1371/journal.pone.0017438.

18.

Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link?

Germano I, Swiss V, Casaccia P.

Neuropharmacology. 2010 May;58(6):903-10. doi: 10.1016/j.neuropharm.2009.12.019. Epub 2010 Jan 1. Review.

19.

Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Chen HZ, Tsai SY, Leone G.

Nat Rev Cancer. 2009 Nov;9(11):785-97. doi: 10.1038/nrc2696. Review.

20.

HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function.

Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R.

Virology. 2008 Jun 5;375(2):611-23. doi: 10.1016/j.virol.2008.02.025. Epub 2008 Mar 26.

Supplemental Content

Support Center